Gene · 9476
Papers2,888
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,888
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report. | Front Oncol | 2023 | 38074660 | PubTator, text mining | PubMed |
| A rare case of hepatoid adenocarcinoma of the lung. | Clin Respir J | 2023 | 38071759 | PubTator, text mining | PubMed |
| Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung. | Cancers (Basel) | 2023 | 38067335 | PubTator, text mining | PubMed |
| The Role of Gene Fusions in Thymic Epithelial Tumors. | Cancers (Basel) | 2023 | 38067300 | PubTator, text mining | PubMed |
| An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. | Cancers (Basel) | 2023 | 38067281 | PubTator, text mining | PubMed |
| Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer. | BMC Cancer | 2023 | 38066448 | PubTator, text mining | PubMed |
| Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma. | Cancer Med | 2023 | 38062922 | PubTator, text mining | PubMed |
| Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy. | J Cytol | 2023 | 38058664 | PubTator, text mining | PubMed |
| Applications of lung cancer organoids in precision medicine: from bench to bedside. | Cell Commun Signal | 2023 | 38057851 | PubTator, text mining | PubMed |
| Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report. | BMC Pulm Med | 2023 | 38057798 | PubTator, text mining | PubMed |
| Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer. | Onco Targets Ther | 2023 | 38050583 | PubTator, text mining | PubMed |
| Cellular crosstalk of macrophages and therapeutic implications in non-small cell lung cancer revealed by integrative inference of single-cell transcriptomics. | Front Pharmacol | 2023 | 38044943 | PubTator, text mining | PubMed |
| Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. | BMC Cancer | 2023 | 38041048 | PubTator, text mining | PubMed |
| Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report. | Heliyon | 2023 | 38034719 | PubTator, text mining | PubMed |
| Metastatic hepatocellular carcinoma of the oral cavity - A report of two cases. | J Oral Maxillofac Pathol | 2023 | 38033937 | PubTator, text mining | PubMed |
| SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report. | Gynecol Oncol Rep | 2023 | 38033359 | PubTator, text mining | PubMed |
| Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report. | Case Rep Oncol | 2023 | 38028574 | PubTator, text mining | PubMed |
| Combined Carcinoid Carcinoma and Squamous Cell Carcinoma of the Endometrium: A Case Report and Survey of Related Literature. | Case Rep Oncol | 2023 | 38028571 | PubTator, text mining | PubMed |
| Machine learning for pan-cancer classification based on RNA sequencing data. | Front Mol Biosci | 2023 | 38028533 | PubTator, text mining | PubMed |
| A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy. | Heliyon | 2023 | 38027958 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9476/papers?page=16